Core Insights - BioStem Technologies Inc. is a leading MedTech company specializing in placental-derived biologics for advanced wound care [1][4] - The company will present at the Morgan Stanley Global Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference in New York [2][5] - BioStem's proprietary BioREtain processing method is designed to maintain growth factors and preserve tissue structure, enhancing the efficacy of its products [4] Company Overview - BioStem Technologies focuses on the development, manufacture, and commercialization of allografts for regenerative therapies [4] - The company’s quality management system is accredited by the American Association of Tissue Banks (AATB) and adheres to current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP) [4] - BioStem's product portfolio includes brands such as AmnioWrap2™, VENDAJE, VENDAJE AC, and VENDAJE OPTIC, all processed at its FDA registered and AATB accredited facility in Pompano Beach, Florida [4]

Core Insights - BioStem Technologies, Inc. disclosed an insider purchase of common stock by Jason Matuszewski, the Chairman and CEO, indicating confidence in the company's future prospects [1][2] Group 1: Insider Transactions - Jason Matuszewski purchased a total of 15,500 shares on August 19, 2025, for approximately $100,000, with transactions executed at average prices of $6.28 for 2,500 shares and $6.51 for 13,000 shares [2] - Following these transactions, Mr. Matuszewski's total ownership in BioStem Technologies increased to 1,145,362 shares [2] Group 2: Company Overview - BioStem Technologies is a MedTech company focused on developing, manufacturing, and commercializing placental-derived products for advanced wound care [1][3] - The company utilizes its proprietary BioREtain processing method, which is designed to maintain growth factors and preserve tissue structure, enhancing the effectiveness of its allografts for regenerative therapies [3] - BioStem's quality management system has been accredited by the American Association of Tissue Banks (AATB) and adheres to current Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP) [3] - The company's product portfolio includes brands such as AmnioWrap2™, VENDAJE, VENDAJE AC, and VENDAJE OPTIC, all processed at its FDA registered and AATB accredited facility in Pompano Beach, Florida [3]

Core Insights - BioStem Technologies, Inc. reported preliminary financial results for Q2 2025, highlighting a sixth consecutive quarter of positive adjusted EBITDA despite facing revenue challenges due to increased competition and reimbursement uncertainties [4][9][11]. Recent Business Highlights - The company appointed Brandon Poe as the new Chief Financial Officer, bringing over 25 years of healthcare finance experience [4][8]. - BioStem completed enrollment in a clinical trial for BioREtain® Amnion Chorion aimed at treating diabetic foot ulcers, with data expected in Q4 2025 [8]. - The commercial organization is expanding with new direct representatives to access additional care sites [8]. - The intellectual property portfolio has been expanded with three new U.S. patent applications, totaling 58 issued and 68 pending patents [8]. Preliminary Financial Highlights - Net revenue for Q2 2025 was $49.3 million, a 34% decrease from Q2 2024, primarily due to lower volumes in the wound care portfolio [9][27]. - Gross profit was $48.6 million, representing 98.6% of net revenue, compared to $70.7 million or 95.0% of net revenue in Q2 2024 [10]. - Operating expenses decreased to $48.5 million from $61.9 million in Q2 2024, driven by lower revenue and reduced sales and marketing costs [10]. - Adjusted EBITDA for Q2 2025 was $2.5 million, down from $10.1 million in Q2 2024, reflecting lower gross profit but offset by reduced operating expenses [11]. - The company reported a GAAP net loss of $0.6 million or ($0.03) per share, compared to net income of $6.3 million or $0.39 per share in Q2 2024 [12][27]. - Cash and cash equivalents increased to $30.8 million as of June 30, 2025, up from $26.7 million as of March 31, 2025 [12][27]. Uplisting and Audit Update - BioStem is pursuing an uplisting to Nasdaq and is currently working through the audit of its historical financial statements [5][6]. - The company has clarified the accounting treatment for its distribution agreement with Venture Medical and is preparing to file an amended Form 10 to address SEC comments [5][6].

Core Insights - BioStem Technologies, Inc. supports the reform of the reimbursement framework for skin substitutes, aiming to address rising Medicare spending in this category [2] - The company is engaged in randomized controlled trials to demonstrate the clinical superiority of its BioREtain technology, which is central to its commercial products [2] - BioStem is in the process of filing Form 10 and plans to provide updates on its Nasdaq uplisting during its second quarter 2025 earnings call [2] Company Overview - BioStem Technologies is focused on developing, manufacturing, and commercializing placental-derived products for advanced wound care [1][3] - The company utilizes its proprietary BioREtain processing method, which preserves growth factors and tissue structure [3] - BioStem's quality management system has been accredited by the American Association of Tissue Banks, adhering to current Good Tissue Practices and Good Manufacturing Processes [3] Industry Context - The Centers for Medicare and Medicaid Services (CMS) has released proposals for the Calendar Year 2026 Physician Fee Schedule and Outpatient Prospective Payment System regarding skin substitute reimbursement [1] - The proposed changes are expected to promote investment in innovation and improve outcomes for patients with chronic wounds [2]

Company Overview - BioStem Technologies, Inc. is a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care [5] - The company utilizes its proprietary BioREtain processing method to maintain growth factors and preserve tissue structure in its allografts [5] Market Position and Opportunities - Jason Matuszewski, Chairman and CEO, will present BioStem's current position in the chronic wound care market and key opportunities for growth at the Advanced Wound Care Summit on July 15, 2025 [1] - The company aims to drive continued growth in its core allograft business while pursuing opportunities to expand its portfolio across the continuum of care [8] Event Details - The Advanced Wound Care Summit will take place from July 15 to 17, 2025, bringing together global leaders in wound care innovation and clinical research [3] - The summit will feature keynote presentations, interactive panels, and strategic networking opportunities to address unmet needs in chronic wound management [3] Quality and Compliance - BioStem's quality management systems and standard operating procedures are accredited by the American Association of Tissue Banks (AATB) and adhere to Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP) [6] - The company's products are processed at an FDA registered and AATB accredited site in Pompano Beach, Florida [6]

Company Overview - BioStem Technologies is a leading MedTech company focused on improving the lives of patients with chronic, non-healing wounds through innovative solutions [3][14] - The company develops and manufactures placental-derived allografts using proprietary BioREtain® technology, which preserves tissue's native properties and optimizes clinical outcomes [3][15] - BioStem's products are used by clinicians nationwide to address the growing demand for advanced wound care solutions [3][14] Leadership Recognition - Jason Matuszewski, CEO and Chairman of BioStem Technologies, was awarded the Entrepreneur Of The Year 2025 Florida Award by Ernst & Young LLP [1][4] - The award recognizes leaders who demonstrate long-term value creation, entrepreneurial spirit, and significant growth and impact [2][5] - Matuszewski emphasized the collective effort of the BioStem team in achieving this recognition, highlighting their commitment to innovation and patient care [3][4] Future Aspirations - As a Florida award winner, Matuszewski is eligible for the Entrepreneur Of The Year 2025 National Awards, with winners announced in November [4] - The National Award winner will compete for the EY World Entrepreneur Of The Year™ Award in June 2026 [4][8] - BioStem aims to expand its impact and continue advancing its platform in the healthcare system [3][14]

Upon SEC approval of the amended Form 10, BioStem expects to advance its uplisting to Nasdaq POMPANO BEACH, Fla., June 03, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. ("BioStem" or the "Company") (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today provides an update on the Company's Form 10 registration statement and SEC review process. BioStem believes it has favorably resolved outstandi ...

Company Overview - BioStem Technologies, Inc. is a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care [4] - The company utilizes its proprietary BioREtain® processing method to maintain growth factors and preserve tissue structure in its products [4] - BioStem's quality management system has been accredited by the American Association of Tissue Banks (AATB) and adheres to current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP) [4] Recent Developments - BioStem Technologies will participate in the Goldman Sachs 46th Annual Global Healthcare Conference in Miami [1] - Jason Matuszewski, the CEO, will engage in a fireside chat and is available for one-on-one meetings with conference attendees [2] Product Portfolio - The company's product brands include AmnioWrap2™, VENDAJE, VENDAJE AC, and VENDAJE OPTIC, all processed at its FDA registered and AATB accredited site in Pompano Beach, Florida [4]

Company Overview - BioStem Technologies, Inc. is a leading MedTech company focused on developing, manufacturing, and commercializing placental-derived products for advanced wound care [1][10] - The company utilizes its proprietary BioREtain processing method to maintain growth factors and preserve tissue structure in its products [10] Recognition and Awards - Jason Matuszewski, CEO of BioStem, has been named a finalist for the Ernst & Young LLP (EY US) Entrepreneur Of The Year 2025 Florida Award, recognizing his entrepreneurial spirit and the company's impact [1][3] - The Entrepreneur Of The Year program celebrates leaders who disrupt markets and make significant contributions to their communities [2][4] Company Impact - BioStem's products have positively affected the lives of patients with chronic wounds across the United States and contributed to the health and economic vitality of Florida [4] - The company emphasizes its commitment to innovation in advanced wound care and acknowledges the contributions of its dedicated team [4] Future Events - Regional award winners for the Entrepreneur Of The Year will be announced on June 13, with winners considered for national recognition at the Strategic Growth Forum in November [5][8]

Core Viewpoint - BioStem Technologies Inc. will release its first quarter 2025 financial results on May 12, 2025, and will host a conference call and webcast to discuss the results [1][2]. Company Overview - BioStem Technologies is a MedTech company focused on developing, manufacturing, and commercializing placental-derived biologics for advanced wound care [1][4]. - The company utilizes its proprietary BioREtain processing method to maintain growth factors and preserve tissue structure in its products [4]. - BioStem's quality management system has been accredited by the American Association of Tissue Banks (AATB) and adheres to current Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP) [4]. Upcoming Events - The conference call and webcast will feature an overview of the quarter from CEO Jason Matuszewski and CFO Michael Fortunato [2]. - Interested parties can register for the event and follow the company on social media for updates [3]. Contact Information - BioStem Technologies can be contacted via phone at 954-380-8342 or through their website [7]. - Investor relations inquiries can be directed to Adam Holdsworth at adam@holdsworthco.com [7].